Cardior Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Cardior Pharmaceuticals is a biotechnology company that engages in the development of non-coding RNA based therapeutics for the treatment and prevention of heart disease. It focuses on developing CDR-132X, an oligonucleotide-based inhibitor of a molecular master switch (microRNA) controlling pathological alterations of the heart following stress or injury. Cardior Pharmaceuticals is a planned academic spin-off developing new therapeutics for the treatment and prevention of heart disease - the number one cause of death in the western world.
Cardior Pharmaceuticals has raised $75.2M across 1 funding round on record, the most recent a Series B of $75.2M announced in Aug 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cardior Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Aug 2021.
Cardior Pharmaceuticals Funding Rounds
Cardior Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Cardior Pharmaceuticals Funding Compared to Other Biotechnology Startups
Cardior Pharmaceuticals' latest round of $75.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cardior Pharmaceuticals in Biotechnology and Hanover
Companies Similar to Cardior Pharmaceuticals
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug…
Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of…
NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and…
Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is…
Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and…
Mbiomics is a company in the field of biotechnology.
At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their…
Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored…
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity.…
Cardior Pharmaceuticals Funding FAQs
What does Cardior Pharmaceuticals do?
Cardior Pharmaceuticals is a biotechnology company that engages in the development of non-coding RNA based therapeutics for the treatment and prevention of heart disease. It focuses on developing CDR-132X, an oligonucleotide-based inhibitor of a molecular master switch (microRNA) controlling pathological alterations of the heart following stress or injury. Cardior Pharmaceuticals is a planned academic spin-off developing new therapeutics for the treatment and prevention of heart disease - the number one cause of death in the western world.
How much funding has Cardior Pharmaceuticals raised?
Cardior Pharmaceuticals has raised $75.2M across 1 round on record. The most recent is a Series B of $75.2M announced in Aug 2021.
When did Cardior Pharmaceuticals last raise funding?
Cardior Pharmaceuticals' most recent funding round on record is a Series B of $75.2M, announced in Aug 2021.
Who is the CEO of Cardior Pharmaceuticals?
Claudia Ulbrich is listed as CEO at Cardior Pharmaceuticals.
Where is Cardior Pharmaceuticals headquartered?
Cardior Pharmaceuticals is based in Hanover, Niedersachsen, Germany.
How many employees does Cardior Pharmaceuticals have?
Cardior Pharmaceuticals is in the 11-50 employee band.
How does Cardior Pharmaceuticals' funding compare to other Biotechnology startups?
Cardior Pharmaceuticals' latest round of $75.2M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Cardior Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cardior Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.